Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension Study

Category Primary study
JournalFrontiers in Neurology
Year 2022
This article has no abstract
Epistemonikos ID: 48f42d63ca44854b8d104f658774ef327120e767
First added on: Feb 13, 2025